Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies

Osteoarthritis and Cartilage

Volumn 23, Issue , 2015, Pages S18-S21

  Hochberg, M C ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Fulranumab; Monoclonal antibodies to nerve growth factor; Osteonecrosis; Rapidly progressive osteoarthritis; Tanezumab

Indexed keywords

CELECOXIB; DICLOFENAC; FULRANUMAB; NAPROXEN; OXYCODONE; PLACEBO; TANEZUMAB; MONOCLONAL ANTIBODY; NERVE GROWTH FACTOR;

ARTHROPATHY; ARTICLE; BONE DESTRUCTION; BONE NECROSIS; CHONDROLYSIS; DISEASE COURSE; HIP OSTEOARTHRITIS; HUMAN; JOINT PROSTHESIS; KNEE OSTEOARTHRITIS; LOW BACK PAIN; MONOTHERAPY; OSTEOARTHRITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; JOINT DISEASES; NERVE GROWTH FACTOR; OSTEONECROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84922648191     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2014.10.005     Document Type: Article

References (38)

1. Cattaneo A. Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain. Curr Opin Mol Ther 2010, 12:94-106.
2. Lane N.E., Schnitzer T.J., Birbara C.A., Mokhtarani M., Shelton D.L., Smith M.D., et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. NEngl J Med 2010, 383:1521-1531.
3. Schnitzer T.J., Lane N.E., Birbara C., Smith M.D., Simpson S.L., Brown M.T. Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain. Osteoarthritis Cartilage 2011, 19:639-646.
4. Evans R.J., Moldwin R.M., Cossons N., Darekar A., Mills I.W., Scholfield D. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. JUrol 2011, 185. 1716-21.
5. Katz N., Borenstein D.G., Birbara C., Bramson C., Nemeth M.A., Smith M.D., et al. Efficacy and safety of tanezumab in the treatment of chronic low back pain. Pain 2011, 152:2248-2258.
6. Nagashima H., Suzuki M., Araki S., Yamabe T., Muto C. Tanezumab investigators: preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study. Osteoarthritis Cartilage 2011, 19:1405-1412.
7. Brown M.T., Murphy F.T., Radin D.M., Davignon I., Smith M.D., West C.R. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial. JPain 2012, 13:790-798.
8. Nickel J.C., Atkinson G., Krieger J.N., Mills I.W., Pontari M., Shoskes D.A., et al. Preliminary assessment of safety and efficacy in proof-of-concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndrome. Urology 2012, 80:1105-1110.
9. Brown M.T., Murphy F.T., Radin D.M., Davignon I., Smith M.D., West C.R. Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial. Arthritis Rheum 2013, 1795-1803.
10. Kivitz A.J., Gimbel J.S., Bramson C., Nemeth M.A., keller D.S., Brown M.T., et al. Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain. Pain 2013, 154:1009-1021.
11. Spierings E.L., Fidelholtz J., Wolfram G., Smith M.D., Brown M.T., West C.R. Aphase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee. Pain 2013, 154:1603-1612.
12. Sanga P., Katz N., Polverejan E., Wang S., Kelly K.M., Haeussler J., et al. Efficacy, safety and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patient with moderate to severe osteoarthritis pain. Pain 2013, 154:1910-1919.
13. Balanescu A.R., Feist E., Wolfram G., Davignon I., Smith M.D., Brown M.T., et al. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicenter phase III randomized clinical trial. Ann Rheum Dis 2013 Jul 12, [Epub ahead of print].
14. Leite V.F., Buehler A.M., El Abd O., Benyamin R.M., Pimentel D.C., Chen J., et al. Anti-nerve growth factor in the treatment of low back pain and radiculopathy: a systematic review and a meta-analysis. Pain Physician 2014, 17:E45-E60.
15. Schnitzer T.J., Ekman E.F., spierings E.L., Greenberg H.S., Smith M.D., Brown M.T., et al. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain. Ann Rheum Dis 2014 Mar 13, [Epub ahead of print].
16. Bannwarth B., Kostine M. Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?. Drugs 2014, 74:619-626.
17. Tanezumab Arthritis Advisory Committee Briefing Document, Pfizer February 8, 2012.
18. Hochberg M.C., Abramson S.B., Hungerford D.S., McCarthy E., Vignon E.P., Smith M.D., et al. Adjudication of reported serious adverse joint events in the tanezumab clinical development program. Arthritis Rheum 2012, 64(10,Suppl l):S113.
19. JNJ-42160443 (fulranumab) Advisory Committee Briefing Document, Janssen Research & Development, L.L.C., January 31, 2012.
20. Moskowitz R., Brandt K., Lequesne M., Mont M.A., Kneeland B., Sanga P., et al. Adjudication process for joint events of interest in fulranumnab clinical trial program. Osteoarthritis Cartilage 2013, 21(Suppl 1):S288-S289.
21. Lequesne M., Amoroux J. Rapidly destructive osteoarthritis of the hip. La Presse Medicale 1970, 78:1435-1439.
22. Della Torre P., Picuti G., Di Filippo P. Rapidly progressive osteoarthritis of the hip. Ital J Orthop Traumatol 1987, 13(2):187-200.
23. Lequesne M. Rapidly progressing destructive diseases of the hip. Ann Radiol (Paris) 1993, 36:62-64.
24. Irwin L.R., Ropberts J.A. Rapidly progressive osteoarthrosis of the hip. JArthoplasty 1998, 13:642-646.
25. Yamamoto T., Schneider R., Bullough P.G. Subchondral insufficiency fracture of the femoral head: histopathologic correlation with MRI. Skeletal Radiol 2001, 30(5):247-254.
26. Boutry N., Paul C., Leroy X., Fredoux D., Migaud H., Cotton A. Rapidly destructive osteoarthritis of the hip: MR imaging findings. Am J Roentgenol 2002, 179:657-663.
27. Yamamoto T., Schneider R., Iwamoto Y., Bullough P.G. Rapid destruction of the hip joint in osteoarthritis. Ann Rheum Dis 2008, 67(12):1783-1784.
28. Yamamoto T., Schneider R., Iwamoto Y., Bullough P.G. Bilateral rapidly destructive arthrosis of the hip joint resulting from subchondral fracture with superimposed secondary osteonecrosis. Skeletal Radiol 2010, 39:189-192.
29. Zywiel M.G., McGrath M.S., Seyler T.M., Marker D.R., Bonutti P.M., Mont M.A. Osteonecrosis of the knee: a review of three disorders. Orthop Clin North Am 2009, 40(2):193-211.
30. Mont M.A., Marker D.R., Zywiel M.G., Carrino J.A. Osteonecrosis of the knee and related conditions. JAm Acad Orthop Surg 2011, 19:482-494.
31. Pivec R., Johnson A.J., Harwin S.F., Mont M.A. Differentiation, diagnosis, and treatment of osteoarthritis, osteonecrosis, and rapidly progressive osteoarthritis. Orthopedics 2013, 36:118-125.
32. Chisholm K.A., Gilchrist J.M. The Charcot joint: a modern neurologic perspective. JClin Neuromuscul Dis 2011, 13(1):1-13.
33. Huskisson E.C., Berry H., Gishen P., Jubb R.W., Whitehead J. Effects of antiinflammatory drugs on the progression of osteoarthritis of the knee. LINK Study Group. Longitudinal Investigation of Nonsteroidal Antiinflammatory Drugs in Knee Osteoarthritis. JRheumatol 1995, 22:1941-1946.
34. Harder A.T., An Y.H. The mechanisms of the inhibitory effects of nonsteroidal anti-inflammatory drugs on bone healing: a concise review. JClin Pharmacol 2003, 43:807-815.
35. Burr D.B., Radin E.L. Microfractures and microcracks in subchondral bone: are they relevant to osteoarthrosis?. Rheum Dis Clin North Am 2003, 29:675-685.
36. Chen M.R., Dragoo J.L. The effect of nonsteroidal anti-inflammatory drugs on tissue healing. Knee Surg Sports Traumatol Arthrosc 2013, 21:540-549.
37. Vuolteenaho K., Moilanen T., Moilanen E. Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 and the bone healing process. Basic Clin Pharmacol Toxicol 2008, 102:10-14.
38. Gerstenfeld L.C., Einhorn T.A. COX inhibitors and their effects on bone healing. Expert Opin Drug Saf 2004, 3:131-136.